1 month
+20.2%
price return
Year to date
+2.9%
price return
Recent earnings
4/4
quarters beat
Big funds
8
hold this stock
News tone
Mixed
50 articles, 7 days
Analysts
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsWhat it reported, what was expected, and what comes next.
Reported Jul 30, 2026
Earnings per share
$8.00 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
Next report
EPS expected
$14.53 to $17.68
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
From the release
The three statements, quarter by quarter.
Sep 2025 to Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| RevenueTotal revenue | $3.75B | $3.88B | $3.61B | $4.29B |
| Cost of what it soldCost of revenue | $521.6M | $584.6M | $669.4M | $576.5M |
| Gross profit | $3.23B | $3.30B | $2.94B | $3.71B |
| What it spent | ||||
| Research and development | $1.56B | $1.63B | $1.65B | $1.63B |
| Sales and adminSelling, general and administrative | $657.8M | $775.0M | $647.7M | $662.1M |
| Total operating expenses | $2.21B | $2.42B | $2.29B | $2.29B |
| What was left | ||||
| Operating profitOperating income | $1.03B | $879.9M | $642.9M | $1.42B |
| Interest on debtInterest expense | $19.3M | $12.2M | $12.9M | $11.0M |
| Profit before tax | $1.76B | $1.04B | $831.2M | $1.53B |
| TaxIncome tax expense | $303.3M | $199.1M | $104.0M | $230.9M |
| Net profitNet income | $1.46B | $844.6M | $727.2M | $1.30B |
| EBITDAEarnings before interest, tax, depreciation, amortisation | $1.92B | $1.20B | $967.3M | $1.66B |
Business quality, value, and expectations at a glance.
Fundamentals
Fairly priced and profitable.
Valuation
Quality
Growth
Filed positions and reported activity tied to this stock.
8 funds hold a position and insiders have been net selling.
Real smart money
Insiders
Politicians
Trend, range, and the price levels that matter.
Technicals
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
$797.0020D support
20D resistance
Returns
Price vs moving averages
Volume pace
Recent coverage and its overall tone.
News
Coverage is mixed
17 bullish · 17 neutral · 16 bearish
Tone of tracked coverage
7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments
NeutralAug 15How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story
Leans bearishAug 15How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story
Leans bearishAug 15Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall
NeutralAug 15Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy
BullishAug 15Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Leans bullishAug 14Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines
Leans bullishAug 14Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
NeutralAug 14
AlphaYou
